We don't really know if 3-71 will show more significant benefits in humans than 2-73 does (or really, whether 3-71 will show any benefits..right?). Transgenic rodents are notoriously poor at predicting efficacy in people. For example, we engineered mice to manifest ab plaques then cured that problem with mabs to remove the plaques...and declared victory (several times.) But that approach doesn't work in non-engineered human beings, even when they naturally manifest beta amyloid plaques.
Lab rats are imperfect models of a human disease. They are not high fidelity analogs of humans.
The results you cite are very good in the rat model. I would call those results highly suggestive.
But to assume the translation from lab rat to humans is a risky assumption.
A P2 trial will test that assumption. If it proves to be that the lab rat results translate in to humans, 3-71 will be a huge success. Those results are certainly strong enough to move forward with trials as Anavex has done with the P1 trial. Now on to a P2 to get an idea of what 3-71 will do in humans.
News 
Market Data 
Discover 
